Novo Nordisk Stock Soars 7.7% on Promising Amycretin Trial Results

Novo Nordisk's stock price jumped by a significant 7.7% today, following the announcement of promising results from a phase 1b/2a clinical trial for amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once-weekly subcutaneous administration. The trial results showed a 9.7% average reduction in body weight over 36 weeks, with mild to moderate gastrointestinal side effects reported. Novo Nordisk expressed its enthusiasm for the results and plans to continue the drug's clinical development.